Welcome

Dear  Subscriber,

Welcome to the second in a new e-newsletter series, ‘BrainMatters News”, brought to you by Sanofi and distributed in association with Irishhealthpro. In this our second edition, our team has reviewed the latest research on bipolar disorder from a range of clinical psychiatric journals and selected and reviewed the following two articles we think you may find interesting:

  • Outcomes for bipolar patients assessed in the French expert center network: A 2-year follow up observational study (FondaMental Advanced Centers of Expertise for Bipolar Disorder: FACE-BD)
  • Childhood maltreatment and the medical morbidity in bipolar disorder: a case control study
     

We hope you find this information of use and we look forward to your feedback.

Sincerely,

The 'BrainMatters News' Team

Outcomes for bipolar patients assessed in the French expert center network: A 2-year follow up observational study (FondaMental Advanced Centers of Expertise for Bipolar Disorder: FACE-BD)
 

Henry C, Godin O, Courtet P, Azorin JM, Gard S, Bellivier F, et al, FACE-BP collaborators.

Bipolar Disord. 2017 Sep 12. doi: 10.1111/bdi.12539.  

In recent years we have witnessed an increasing interest in the emergence of units specialised in the treatment of bipolar disorder. Different evidence suggests a higher level of quality of healthcare and...

 

Read more
Childhood maltreatment and the medical morbidity in bipolar disorder: a case control study
 

Hosang GM, Fisher HL, Uher R, Cohen-Woods S, Maughan B, McGuffin P, et al.  

 

Int J Bipolar Disord. 2017 Sep 7;5(1):30. doi: 10.1186/s40345-017-0099-z.

 

Several studies have found a relationship between maltreatment suffered in childhood, abuse as well as neglect, with a higher risk of developing a bipolar disorder in adulthood. Recent data also suggest a potential link between...

 

Read more




Legal category: POM. Further information is available from Sanofi, 18 Riverwalk, Citywest Business Campus, Dublin 24

SAFETY WARNING FOR WOMEN AND GIRLS: Valproate should not be prescribed to female children, female adolescents, women of childbearing potential or pregnant women unless other treatments are ineffective or not tolerated.1,2




 

SAIE.VPA.17.10.0212bDate of Preparation: December 2017

 

You are receiving this email because you have agreed to receive information from Sanofi or irishhealthpro.com. If you no longer wish to receive emails from the BrainMatters News' series please click on the unsubscribe link.
Please note this email is intended for health care professionals only.

 

References:

1. Epilim Chrono (200 mg, 300 mg, 500 mg) Summary of Product Characteristics. 
2. Epilim Chronosphere (100 mg, 250 mg, 500 mg) Summary of Product Characteristics.